By the numbers: Series A rounds are busting out, platforms are in, M&A is down, valuations surge and 2018 looks wicked big
Every 6 months we seem to get a new round of record numbers for biopharma. And H1 is no exception.
Silicon Valley Bank …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
